Physicians’ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients

Abstract

Abstract We investigated factors that physicians consider of most importance in the selection of second line tyrosine kinase inhibitors treatments (TKIs) in chronic myeloid leukemia patients (CML).

Keywords

• Chronic myeloid leukemia
• Line of therapy
• Tyrosine Kinase inhibitors